| Date |
Title |
| 23-Dec-2004 |
Xyzal®* Is The First And Only Antihistamine Licensed For Persistent Allergic Rhinitis |
| 17-Dec-2004 |
UCB: research budget for 2005 up significantly after conversion to biopharmaceutics |
| 09-Dec-2004 |
The European Commission Fines Several Companies For Anticompetitive Practices In The Choline Chloride Sector For Animal Feed |
| 03-Dec-2004 |
UCB: Inauguration of New Keppra Production Unit |
| 03-Dec-2004 |
H.R.H. Prince Philippe of Belgium Visits The UCB Site In Braine-l'Alleud Together With The Walloon Authorities |
| 02-Dec-2004 |
UCB announces positive new products results |
| 20-Oct-2004 |
UCB confirms third quarter Zyrtec sales in the US / 6% Increase in European Allergy Franchise |
| 18-Oct-2004 |
UCB appoints Chief Financial Officer |
| 01-Oct-2004 |
UCB sells Surface Specialties to Cytec for € 1.5 billion |
| 30-Sep-2004 |
UCB: Closing of the sale of its films business |
| 21-Sep-2004 |
UCB Pharma outlines positive preliminary results from second pivotal CDP 870 Phase III trial in rheumatoid arthritis |
| 03-Sep-2004 |
Georges Jacobs announces that he will resign from his executive post on January 1, 2005 |
| 02-Sep-2004 |
Sale of an industrial site in France |
| 26-Aug-2004 |
Reorganisation of research |
| 29-Jul-2004 |
Net profit increases by 34% |
| 19-Jul-2004 |
UCB has signed an agreement to sell its Films business |
| 09-Jul-2004 |
UCB has over 90% of Celltech Shares |
| 24-Jun-2004 |
UCB Pharma* announces unique mode of action for Keppra ® |
| 21-Jun-2004 |
UCB Pharma announces granting of European marketing authorisation for innovative transdermal therapy for symptomatic treatment of urge incontinence |
| 08-Jun-2004 |
Annual General Meeting of UCB Shareholders |
| 18-May-2004 |
Celltech and UCB Reach Worldwide Agreement on Development and Marketing of CDP870 |
| 18-May-2004 |
UCB S.A. launches a friendly offer to acquire Celltech Group plc, the leading UK-based biotech company |
| 27-Apr-2004 |
UCB 44212, the second analogue of UCB Pharma’s anti-epileptic, KEPPRA*, enters clinical study phase |
| 25-Mar-2004 |
UCB Group: confirmed increase of 2% in net results |
| 22-Mar-2004 |
UCB Group : Keppra® Patent |
| 06-Feb-2004 |
UCB - Acquisition of innovative treatments in allergy |
| 06-Feb-2004 |
UCB Pharma announces partnership with Dynavax to develop and market products for the treatment of allergies |
| 04-Feb-2004 |
UCB Group - Provisional Results for 2003: Increase in Net Profit. |
| 18-Dec-2003 |
UCB: Confidence in the future - Significant Programmes for R&D and Investment for the Year 2004. |
| 22-Oct-2003 |
UCB: Third quarter Zyrtec sales in the US |
| 30-Sep-2003 |
UCB : Closing of the sale of Methylamines & Derivatives Activities |
| 24-Sep-2003 |
UCB Pharma enters European licensing agreement with Watson |
| 22-Sep-2003 |
UCB : New Director-General of the Pharma Sector |
| 16-Sep-2003 |
UCB invests in new production unit of Radcure monomers |
| 16-Aug-2003 |
UCB : Sale of Methylamines & Derivatives Activities |
| 29-Jul-2003 |
UCB Group : 2003 first half-year result |
| 10-Jun-2003 |
UCB : Profits for 2003 essentially affected by the fall in the dollar. |
| 09-May-2003 |
UCB Inaugurates North American Pharma Headquarters. |
| 22-Apr-2003 |
UCB: First quarter Zyrtec sales in the US. |
| 01-Apr-2003 |
Data analysis shows Keppra® reduced partial seizures in nearly 80 percent of elderly patients in a community-based trial. |
| 14-Mar-2003 |
UCB Group : confirmation of an increase in ordinary profits of 7%. |
| 26-Feb-2003 |
Celltech Group PLC (CCH) - Offer for Oxford GlycoScience |
| 06-Feb-2003 |
The UCB Group in 2002: Preliminary Unaudited Profits. Record Ordinary Profits before Tax of € 494 million, an increase of 7% |
| 31-Jan-2003 |
UCB closes on its acquisition of Solutia's Resins, Additives and Adhesives businesses |
| 22-Jan-2003 |
UCB : Fourth quarter year-to-date Zyrtec sales in the US increase by 13%. |
| 14-Jan-2003 |
UCB: Acquisition in the field of Specialty Chemicals |
